Pro Research: Wall Street dives into Neurocrine Biosciences

  • Stock Market News
Pro Research: Wall Street dives into Neurocrine Biosciences

Explore Wall Street's expert insights with this ProResearch article, which will exclusively be available to InvestingPro subscribers soon. Enhance your investment strategy with ProPicks, our newest product featuring strategies that have outperformed the S&P 500 by up to 700%. This Cyber Monday, enjoy up to 60% off, plus an extra 10% off a 2-year subscription with the code research23, reserved for the first 500 quick subscribers. To ensure ongoing access to valuable content like this, step up your investment game with InvestingPro.

In a competitive and ever-evolving biopharmaceutical landscape, Neurocrine (NASDAQ: NBIX ) Biosciences, Inc. ( NASDAQ : NBIX) stands out with its focus on neurological and endocrine-related diseases and disorders. Analysts have been closely monitoring the company's performance and pipeline developments, providing insights that are crucial for investors looking to understand the potential risks and rewards associated with NBIX.

Performance in Different Markets

The core product of Neurocrine Biosciences, Ingrezza, used to treat Tardive Dyskinesia, has been performing robustly, with sales growth outpacing expectations. The company has raised its revenue guidance for Ingrezza, signaling confidence in the drug's market penetration and long-term prospects. The recent approval of Ingrezza for Huntington's Chorea also marks a significant milestone, expanding the drug's therapeutic reach.

Product Segments and Pipeline

Neurocrine's pipeline is a mix of promise and setbacks. Two mid-stage pipeline programs, '352 for epilepsy and '864 for anhedonia, faced discontinuation after failing to meet clinical trial endpoints. These failures have cast some doubt on the company's ability to diversify its portfolio. However, the recent success of crinecerfont in phase III trials for congenital adrenal hyperplasia (CAH) has been a silver lining, potentially setting the stage for a new blockbuster product.

The upcoming phase II readouts for '352 in focal onset seizures and the muscarinic program are being watched closely, as they could significantly impact the company's valuation and diversification strategy.

Competitive Landscape and Market Trends

Neurocrine operates in a highly competitive market, where innovation and timely product development are key. Despite setbacks, the company is expected to focus on strategic acquisitions to bolster its pipeline. Analysts are also speculating about the company's potential as an acquisition target itself, given its strong product Ingrezza and promising pipeline candidates.

Regulatory Environment and Customer Base

The regulatory environment is a critical factor for Neurocrine. The company is preparing for regulatory milestones, including a pre-NDA meeting for crinecerfont and potential filings. Analysts anticipate that the company will navigate through these milestones effectively, which could lead to significant value appreciation.

Management and Strategy

Under new leadership, Neurocrine has been refocusing on validated biology and lower-risk innovation. The strategic pivot is expected to leverage the company's core strengths and improve its risk profile, as reflected by the maintained "Overweight" rating by analysts.

External Factors

The Inflation Reduction Act (IRA) has been a point of concern for analysts, with potential impacts on long-term Ingrezza prospects due to changes in drug pricing and reimbursement.

Upcoming Product Launches

Crinecerfont's upcoming launch, following a likely approval towards the end of 2024, is highly anticipated. The drug's potential for treating CAH could position it as a standard treatment with a significant market share.

Stock Performance

Neurocrine's stock has seen fluctuations in response to pipeline developments and market conditions. Analysts have provided varied price targets, reflecting their individual assessments of the company's risk-reward scenario and future prospects.

Bear Case

Is Neurocrine Biosciences facing significant pipeline risks?

Neurocrine has experienced pipeline setbacks, most notably with the failure of '352 for epilepsy and '864 for anhedonia. These failures limit the company's ability to diversify beyond Ingrezza, raising concerns about its long-term growth potential. Analysts have adjusted their price targets accordingly, reflecting increased risk perceptions and the need for strategic decisions to rebuild the pipeline.

Will Neurocrine's reliance on Ingrezza affect its growth prospects?

Despite Ingrezza's strong sales, there is skepticism about the drug's ability to sustain long-term growth, particularly with the potential impact of the IRA. The company's reliance on this single product could pose risks to its valuation if pipeline developments do not yield successful new treatments.

Bull Case

Can Neurocrine Biosciences capitalize on its recent clinical successes?

The success of crinecerfont in phase III trials for CAH has been a significant boost for Neurocrine. Analysts believe that this drug has the potential to become a standard treatment for CAH, with a high probability of regulatory approval. The company's strategic acquisitions and focus on low-risk innovation could further enhance its growth trajectory.

Is the market underestimating Neurocrine's potential catalysts?

Upcoming catalysts, including phase II readouts for '352 in focal onset seizures and the muscarinic program, could provide significant upside for Neurocrine. Analysts remain optimistic about the company's ability to deliver on these fronts, which could lead to a revaluation of NBIX shares.

SWOT Analysis


  • Strong sales performance of Ingrezza.
  • Positive phase III trial results for crinecerfont in CAH.
  • Strategic focus on low-risk innovation and validated biology.


  • Pipeline setbacks with the failure of two mid-stage programs.
  • Heavy reliance on Ingrezza for revenue.
  • Potential impact of IRA on long-term prospects.


  • Market expansion through strategic acquisitions.
  • Upcoming product launches and pipeline readouts.
  • Untapped market potential for Tardive Dyskinesia treatment.


  • Competitive market with rapid innovation.
  • Regulatory hurdles and insurance coverage issues.
  • Execution risks in commercializing new products.

Analyst Targets

  • Barclays (LON: BARC ) Capital Inc.: Overweight rating with a price target of $135.00 (November 1, 2023).
  • BMO Capital Markets Corp.: Market Perform rating with a price target of $111.00 (November 1, 2023).
  • RBC Capital Markets: Sector Perform rating with a price target of $128.00 (November 1, 2023).
  • Piper Sandler: Neutral rating with a price target of $100.00 (November 1, 2023).

The analysis timeframe spans from September to November 2023.

InvestingPro Insights

As investors evaluate the potential of Neurocrine Biosciences, Inc. (NASDAQ: NBIX), real-time data and expert analysis from InvestingPro provide a deeper understanding of the company's financial health and market position. With an adjusted market capitalization of $11.45 billion, Neurocrine Biosciences is a significant player in the biopharmaceutical industry. The company's P/E ratio stands at 59.48, which may initially seem high, but when adjusted for the last twelve months as of Q3 2023, it lowers to 37.42, reflecting a more favorable earnings outlook. Furthermore, the PEG ratio for the same period is notably low at 0.28, indicating that the company's earnings growth could be undervalued relative to its peers.

InvestingPro Tips highlight that Neurocrine Biosciences yields a high return on invested capital and that analysts are optimistic about net income growth this year. Additionally, the company is trading at a low P/E ratio relative to near-term earnings growth, which could suggest an attractive valuation for investors considering the stock's future potential. These insights are particularly relevant as Neurocrine Biosciences prepares for upcoming product launches and navigates the competitive landscape.

For those seeking comprehensive analysis, InvestingPro offers additional tips on the company's financials and market performance. With a special Cyber Monday sale, investors can now access InvestingPro with a discount of up to 60%, and use the coupon code research23 to get an additional 10% off a 2-year InvestingPro+ subscription. There are currently 18 additional InvestingPro Tips listed for Neurocrine Biosciences, providing subscribers with an extensive range of data points and expert opinions to inform their investment decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or